Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Apr 2019
Price : $35 *
At a glance
- Drugs Pramlintide (Primary)
- Indications Hypoglycaemia
- Focus Proof of concept; Therapeutic Use
- 04 Apr 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified April 2017).
- 31 Aug 2018 Biomarkers information updated
- 25 Apr 2017 Planned End Date changed from 1 May 2015 to 1 Oct 2018.